ImCheck Therapeutics
Created in 2015
- BETA
Up & running (A)
Existing signals show a regular activity Social networks
552 8,142Global tags
Activities
Technologies
Entity types
Location
31 Chemin Joseph Aiguier, CS 70071 13402, MARSEILLE Cedex 20, 13009 Marseille, France
Marseille
France
Employees
Scale: 11-50
Estimated: 51
SIREN
812428142Engaged corporates
28
13 18Added in Motherbase
3 years, 6 months ago
biotech Value proposition
Bringing a novel class of Butyrophilin-targeted checkpoint modulators into the clinic
ImCheck Therapeutics is designing and developing a new generation of immunotherapeutic antibodies targeting butyrophilins, a novel super-family of immunomodulators.
As demonstrated by lead clinical-stage program ICT01, which has a mechanism of action to simultaneously modulate innate and adaptive immunity, ImCheck's “first-in-class” activating antibodies may be able to produce superior clinical results as compared to the first-generation of immune checkpoint inhibitors and, when used in combination, to overcome resistance to this group of agents. In addition, ImCheck’s antagonist antibodies are being evaluated as potential treatments for a range of autoimmune diseases.
Co-founder of the Marseille Immunopole cluster, ImCheck benefits from support from Prof. Daniel Olive (INSERM, CNRS, Institut Paoli Calmettes, Aix-Marseille Université), a worldwide leader in γδ T cells and butyrophilins research; from the experience of an expert management team; and from the commitment of leading US and European investors.
antibodies, immuno-oncology, Immune checkpoint Modulators, Auto-immunity, innate immunity, oncology, cancer, precision-based medicine, adaptative immunity, EVICTIONtrial, ICT01, and gamma-deltaTcellsOriginal language
Bringing a novel class of Butyrophilin-targeted checkpoint modulators into the clinic
ImCheck Therapeutics is designing and developing a new generation of immunotherapeutic antibodies targeting butyrophilins, a novel super-family of immunomodulators.
As demonstrated by lead clinical-stage program ICT01, which has a mechanism of action to simultaneously modulate innate and adaptive immunity, ImCheck's “first-in-class” activating antibodies may be able to produce superior clinical results as compared to the first-generation of immune checkpoint inhibitors and, when used in combination, to overcome resistance to this group of agents. In addition, ImCheck’s antagonist antibodies are being evaluated as potential treatments for a range of autoimmune diseases.
Co-founder of the Marseille Immunopole cluster, ImCheck benefits from support from Prof. Daniel Olive (INSERM, CNRS, Institut Paoli Calmettes, Aix-Marseille Université), a worldwide leader in γδ T cells and butyrophilins research; from the experience of an expert management team; and from the commitment of leading US and European investors.
Imchecktherapeutics.com: Imcheck Therapeutics
Imcheck Therapeutics : Opening new spaces in Immuno-Oncology.
https://imchecktherapeutics.com/
| Corporate | Type | Tweets | Articles | |
|---|---|---|---|---|
 | Gouvernement | Other 16 Jun 2023 | | |
 | Ministère de la Santé | Other 16 Jun 2023 | | |
 NEFTYS Finance, Financial Services | NEFTYS Finance, Financial Services | Other 2 Jul 2023 | | |
 Ministère de l'Enseignement supérieur et de la Recherche Government Administration | Ministère de l'Enseignement supérieur et de la Recherche Government Administration | Other 16 Jun 2023 | | |
 La Coque Events Services | La Coque Events Services | Other 10 Mar 2023 | | |
 CNRS Innovation Research, Research Services | CNRS Innovation Research, Research Services | Other 21 Feb 2023 | | |
 La French Tech Media, Government Administration | La French Tech Media, Government Administration | Not capitalistic Not partnership Event 23 Sep 2023 | | |
 Gimv Financial Services | Gimv Financial Services | Other 23 Sep 2023 | | |
 Go Entrepreneurs Events Services | Go Entrepreneurs Events Services | Other 20 Oct 2022 | | |
 Pouss@LYS Financial Services | Pouss@LYS Financial Services | Other 15 Sep 2022 | | |